HOPE Therapeutics™, Inc. (“HOPE”), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announces the signing of a binding Letter of Intent (the “LOI”) to purchase a 49% interest in Cohen and Associates, LLC (“Cohen”), founded by Dr. Rebecca Cohen. Cohen is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida. Cohen is one of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation (“TMS”) as well as medication management.
Read the full article: HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC //
Source: https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-agreement-to-acquire-interest-in-cohen-and-associates-llc-for-hopes-network-of-interventional-psychiatry-clinics-302492190.html